Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XC221 in Influenza and ARVI
NCT03455491Phase 2Completed
- Sponsor
- PHARMENTERPRISES LLC
- Start
- Feb 2018
- Primary completion
- Jun 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of aterixen in influenza, acute respiratory viral infection (ARVI), sponsored by PHARMENTERPRISES LLC. Started Feb 2018; status: completed.
02
Drugs
aterixen
03
Conditions
influenzaacute respiratory viral infection (ARVI)
Beyond the preview
Go deeper on NCT03455491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03455491.